Amin A - Search Results

1

Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States.

Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Amin A, et al. Clin Appl Thromb Hemost. 2016 Jan;22(1):5-11. doi: 10.1177/1076029615585991. Epub 2015 May 19. Clin Appl Thromb Hemost. 2016. PMID: 25993994 Free article. Review.

2

Appropriate thromboprophylaxis in hospitalized cancer patients.

Amin A, Stemkowski S, Lin J, Yang G. Amin A, et al. Clin Adv Hematol Oncol. 2008 Dec;6(12):910-20. Clin Adv Hematol Oncol. 2008. PMID: 19209141

3

Clinical and economic outcomes with appropriate or partial prophylaxis.

Amin AN, Lin J, Johnson BH, Schulman KL. Amin AN, et al. Thromb Res. 2010 Jun;125(6):513-7. doi: 10.1016/j.thromres.2009.10.018. Thromb Res. 2010. PMID: 19931121

4

Lack of thromboprophylaxis across the care continuum in US medical patients.

Amin A, Lin J, Ryan A. Amin A, et al. Hosp Pract (1995). 2010 Jun;38(3):17-25. doi: 10.3810/hp.2010.06.311. Hosp Pract (1995). 2010. PMID: 20499769

5

Appropriate VTE prophylaxis is associated with lower direct medical costs.

Amin A, Hussein M, Battleman D, Lin J, Stemkowski S, Merli GJ. Amin A, et al. Hosp Pract (1995). 2010 Nov;38(4):130-7. doi: 10.3810/hp.2010.11.350. Hosp Pract (1995). 2010. PMID: 21068537

6

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.

Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Deitelzweig S, et al. Among authors: amin a. J Med Econ. 2012;15(4):776-85. doi: 10.3111/13696998.2012.680555. Epub 2012 Apr 13. J Med Econ. 2012. PMID: 22449118 Free article.

7

New options for anticoagulation following total hip arthroplasty and total knee arthroplasty: new oral agents on the horizon.

Amin A. Amin A. Hosp Pract (1995). 2012 Aug;40(3):19-26. doi: 10.3810/hp.2012.08.986. Hosp Pract (1995). 2012. PMID: 23086091 Review.

8

Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients.

Amin A, Stokes M, Wu N, Gatt E, Makenbaeva D, Wiederkehr D, Boulanger L. Amin A, et al. Curr Med Res Opin. 2013 Oct;29(10):1253-61. doi: 10.1185/03007995.2013.818967. Epub 2013 Jul 18. Curr Med Res Opin. 2013. PMID: 23796193

9

Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.

Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH. Amin A, et al. J Med Econ. 2014 Nov;17(11):771-81. doi: 10.3111/13696998.2014.953682. Epub 2014 Aug 26. J Med Econ. 2014. PMID: 25133458 Free article.

10

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks.

Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Deitelzweig S, et al. Among authors: amin a. Cardiol Ther. 2013 Dec;2(2):165-70. doi: 10.1007/s40119-013-0020-5. Epub 2013 Aug 17. Cardiol Ther. 2013. PMID: 25135394 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,923 results

Search Page

Filters